Rationale And Design Of CURRENT-OASIS 7 Study Published In American Heart Journal

Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing regimens of Plavix® (clopidogrel bisulfate) and aspirin on cardiovascular outcomes and bleeding complications in patients with acute coronary syndrome (ACS) who are intended to undergo intervention with coronary angioplasty.

More: continued here

Filed under: Blood on November 7th, 2008